nodes	percent_of_prediction	percent_of_DWPC	metapath
Triazolam—CYP3A5—Sulfasalazine—ankylosing spondylitis	0.109	0.175	CbGbCtD
Triazolam—CYP3A7—Dexamethasone—ankylosing spondylitis	0.0723	0.116	CbGbCtD
Triazolam—CYP3A7-CYP3A51P—Dexamethasone—ankylosing spondylitis	0.0723	0.116	CbGbCtD
Triazolam—CYP3A4—Methylprednisolone—ankylosing spondylitis	0.0559	0.09	CbGbCtD
Triazolam—CYP3A5—Dexamethasone—ankylosing spondylitis	0.0543	0.0873	CbGbCtD
Triazolam—CYP2C8—Dexamethasone—ankylosing spondylitis	0.0522	0.0839	CbGbCtD
Triazolam—CYP3A4—Triamcinolone—ankylosing spondylitis	0.0424	0.0682	CbGbCtD
Triazolam—CYP2C9—Dexamethasone—ankylosing spondylitis	0.0364	0.0585	CbGbCtD
Triazolam—CYP3A4—Betamethasone—ankylosing spondylitis	0.0364	0.0585	CbGbCtD
Triazolam—CYP3A4—Prednisolone—ankylosing spondylitis	0.0359	0.0577	CbGbCtD
Triazolam—CYP3A4—Prednisone—ankylosing spondylitis	0.0339	0.0545	CbGbCtD
Triazolam—CYP3A4—Dexamethasone—ankylosing spondylitis	0.0212	0.034	CbGbCtD
Triazolam—Amnesia—Methylprednisolone—ankylosing spondylitis	0.00205	0.00576	CcSEcCtD
Triazolam—Mood swings—Prednisolone—ankylosing spondylitis	0.00199	0.00559	CcSEcCtD
Triazolam—Osteoarthritis—Triamcinolone—ankylosing spondylitis	0.00193	0.00543	CcSEcCtD
Triazolam—Osteoarthritis—Methylprednisolone—ankylosing spondylitis	0.00193	0.00541	CcSEcCtD
Triazolam—Glossitis—Methotrexate—ankylosing spondylitis	0.00191	0.00536	CcSEcCtD
Triazolam—Affect lability—Triamcinolone—ankylosing spondylitis	0.0019	0.00534	CcSEcCtD
Triazolam—Affect lability—Methylprednisolone—ankylosing spondylitis	0.0019	0.00533	CcSEcCtD
Triazolam—Dysarthria—Methotrexate—ankylosing spondylitis	0.00186	0.00522	CcSEcCtD
Triazolam—Muscular weakness—Prednisolone—ankylosing spondylitis	0.00185	0.0052	CcSEcCtD
Triazolam—Visual disturbance—Betamethasone—ankylosing spondylitis	0.00185	0.0052	CcSEcCtD
Triazolam—Visual disturbance—Dexamethasone—ankylosing spondylitis	0.00185	0.0052	CcSEcCtD
Triazolam—Irritability—Methylprednisolone—ankylosing spondylitis	0.00184	0.00517	CcSEcCtD
Triazolam—Mood swings—Triamcinolone—ankylosing spondylitis	0.00183	0.00514	CcSEcCtD
Triazolam—Mood swings—Methylprednisolone—ankylosing spondylitis	0.00183	0.00513	CcSEcCtD
Triazolam—Euphoric mood—Prednisone—ankylosing spondylitis	0.00181	0.00508	CcSEcCtD
Triazolam—Sweating increased—Prednisolone—ankylosing spondylitis	0.00177	0.00497	CcSEcCtD
Triazolam—Osteoarthritis—Dexamethasone—ankylosing spondylitis	0.00175	0.00492	CcSEcCtD
Triazolam—Osteoarthritis—Betamethasone—ankylosing spondylitis	0.00175	0.00492	CcSEcCtD
Triazolam—Affect lability—Dexamethasone—ankylosing spondylitis	0.00173	0.00485	CcSEcCtD
Triazolam—Affect lability—Betamethasone—ankylosing spondylitis	0.00173	0.00485	CcSEcCtD
Triazolam—Muscular weakness—Triamcinolone—ankylosing spondylitis	0.00171	0.00479	CcSEcCtD
Triazolam—Muscular weakness—Methylprednisolone—ankylosing spondylitis	0.0017	0.00478	CcSEcCtD
Triazolam—Depressed level of consciousness—Methotrexate—ankylosing spondylitis	0.0017	0.00477	CcSEcCtD
Triazolam—Irritability—Dexamethasone—ankylosing spondylitis	0.00167	0.0047	CcSEcCtD
Triazolam—Irritability—Betamethasone—ankylosing spondylitis	0.00167	0.0047	CcSEcCtD
Triazolam—Mood swings—Betamethasone—ankylosing spondylitis	0.00166	0.00466	CcSEcCtD
Triazolam—Mood swings—Dexamethasone—ankylosing spondylitis	0.00166	0.00466	CcSEcCtD
Triazolam—Sweating increased—Triamcinolone—ankylosing spondylitis	0.00163	0.00457	CcSEcCtD
Triazolam—Amnesia—Prednisone—ankylosing spondylitis	0.00163	0.00456	CcSEcCtD
Triazolam—Sweating increased—Methylprednisolone—ankylosing spondylitis	0.00162	0.00456	CcSEcCtD
Triazolam—Muscular weakness—Betamethasone—ankylosing spondylitis	0.00155	0.00434	CcSEcCtD
Triazolam—Muscular weakness—Dexamethasone—ankylosing spondylitis	0.00155	0.00434	CcSEcCtD
Triazolam—Osteoarthritis—Prednisone—ankylosing spondylitis	0.00153	0.00429	CcSEcCtD
Triazolam—Affect lability—Prednisone—ankylosing spondylitis	0.0015	0.00422	CcSEcCtD
Triazolam—Sweating increased—Dexamethasone—ankylosing spondylitis	0.00148	0.00415	CcSEcCtD
Triazolam—Sweating increased—Betamethasone—ankylosing spondylitis	0.00148	0.00415	CcSEcCtD
Triazolam—Irritability—Prednisone—ankylosing spondylitis	0.00146	0.00409	CcSEcCtD
Triazolam—Mood swings—Prednisone—ankylosing spondylitis	0.00145	0.00406	CcSEcCtD
Triazolam—Hepatic failure—Methotrexate—ankylosing spondylitis	0.00142	0.00399	CcSEcCtD
Triazolam—Visual impairment—Prednisolone—ankylosing spondylitis	0.0014	0.00393	CcSEcCtD
Triazolam—Muscular weakness—Prednisone—ankylosing spondylitis	0.00135	0.00378	CcSEcCtD
Triazolam—Visual disturbance—Methotrexate—ankylosing spondylitis	0.00135	0.00378	CcSEcCtD
Triazolam—Hallucination—Methylprednisolone—ankylosing spondylitis	0.00133	0.00373	CcSEcCtD
Triazolam—Sweating increased—Prednisone—ankylosing spondylitis	0.00129	0.00361	CcSEcCtD
Triazolam—Visual impairment—Methylprednisolone—ankylosing spondylitis	0.00129	0.00361	CcSEcCtD
Triazolam—Osteoarthritis—Methotrexate—ankylosing spondylitis	0.00128	0.00358	CcSEcCtD
Triazolam—Erythema—Prednisolone—ankylosing spondylitis	0.00127	0.00355	CcSEcCtD
Triazolam—Irritability—Methotrexate—ankylosing spondylitis	0.00122	0.00342	CcSEcCtD
Triazolam—Mood swings—Methotrexate—ankylosing spondylitis	0.00121	0.00339	CcSEcCtD
Triazolam—Hallucination—Dexamethasone—ankylosing spondylitis	0.00121	0.00339	CcSEcCtD
Triazolam—Hallucination—Betamethasone—ankylosing spondylitis	0.00121	0.00339	CcSEcCtD
Triazolam—Ataxia—Methotrexate—ankylosing spondylitis	0.0012	0.00337	CcSEcCtD
Triazolam—Ill-defined disorder—Prednisolone—ankylosing spondylitis	0.00117	0.0033	CcSEcCtD
Triazolam—Visual impairment—Dexamethasone—ankylosing spondylitis	0.00117	0.00328	CcSEcCtD
Triazolam—Visual impairment—Betamethasone—ankylosing spondylitis	0.00117	0.00328	CcSEcCtD
Triazolam—Erythema—Triamcinolone—ankylosing spondylitis	0.00116	0.00327	CcSEcCtD
Triazolam—Erythema—Methylprednisolone—ankylosing spondylitis	0.00116	0.00326	CcSEcCtD
Triazolam—Malaise—Prednisolone—ankylosing spondylitis	0.00114	0.0032	CcSEcCtD
Triazolam—Dysgeusia—Triamcinolone—ankylosing spondylitis	0.00114	0.0032	CcSEcCtD
Triazolam—Syncope—Prednisolone—ankylosing spondylitis	0.00114	0.00319	CcSEcCtD
Triazolam—GABRQ—Orphan transporters—ANO6—ankylosing spondylitis	0.00113	0.0516	CbGpPWpGaD
Triazolam—Loss of consciousness—Prednisolone—ankylosing spondylitis	0.00111	0.00312	CcSEcCtD
Triazolam—Hypertension—Prednisolone—ankylosing spondylitis	0.00109	0.00307	CcSEcCtD
Triazolam—Ill-defined disorder—Triamcinolone—ankylosing spondylitis	0.00108	0.00303	CcSEcCtD
Triazolam—Ill-defined disorder—Methylprednisolone—ankylosing spondylitis	0.00108	0.00303	CcSEcCtD
Triazolam—Discomfort—Prednisolone—ankylosing spondylitis	0.00106	0.00299	CcSEcCtD
Triazolam—Erythema—Dexamethasone—ankylosing spondylitis	0.00106	0.00296	CcSEcCtD
Triazolam—Erythema—Betamethasone—ankylosing spondylitis	0.00106	0.00296	CcSEcCtD
Triazolam—Hallucination—Prednisone—ankylosing spondylitis	0.00105	0.00295	CcSEcCtD
Triazolam—Malaise—Triamcinolone—ankylosing spondylitis	0.00105	0.00295	CcSEcCtD
Triazolam—Malaise—Methylprednisolone—ankylosing spondylitis	0.00105	0.00294	CcSEcCtD
Triazolam—Syncope—Triamcinolone—ankylosing spondylitis	0.00104	0.00293	CcSEcCtD
Triazolam—Syncope—Methylprednisolone—ankylosing spondylitis	0.00104	0.00292	CcSEcCtD
Triazolam—Oedema—Prednisolone—ankylosing spondylitis	0.00103	0.0029	CcSEcCtD
Triazolam—Dysuria—Methotrexate—ankylosing spondylitis	0.00103	0.0029	CcSEcCtD
Triazolam—Loss of consciousness—Triamcinolone—ankylosing spondylitis	0.00102	0.00287	CcSEcCtD
Triazolam—Loss of consciousness—Methylprednisolone—ankylosing spondylitis	0.00102	0.00287	CcSEcCtD
Triazolam—Shock—Prednisolone—ankylosing spondylitis	0.00102	0.00285	CcSEcCtD
Triazolam—Tachycardia—Prednisolone—ankylosing spondylitis	0.00101	0.00283	CcSEcCtD
Triazolam—Hypertension—Triamcinolone—ankylosing spondylitis	0.00101	0.00282	CcSEcCtD
Triazolam—Hypertension—Methylprednisolone—ankylosing spondylitis	0.001	0.00281	CcSEcCtD
Triazolam—Hyperhidrosis—Prednisolone—ankylosing spondylitis	0.000999	0.0028	CcSEcCtD
Triazolam—Anxiety—Methylprednisolone—ankylosing spondylitis	0.000986	0.00277	CcSEcCtD
Triazolam—Drowsiness—Methotrexate—ankylosing spondylitis	0.000984	0.00276	CcSEcCtD
Triazolam—Ill-defined disorder—Betamethasone—ankylosing spondylitis	0.00098	0.00275	CcSEcCtD
Triazolam—Ill-defined disorder—Dexamethasone—ankylosing spondylitis	0.00098	0.00275	CcSEcCtD
Triazolam—Discomfort—Triamcinolone—ankylosing spondylitis	0.000979	0.00275	CcSEcCtD
Triazolam—Discomfort—Methylprednisolone—ankylosing spondylitis	0.000977	0.00274	CcSEcCtD
Triazolam—Dry mouth—Triamcinolone—ankylosing spondylitis	0.000969	0.00272	CcSEcCtD
Triazolam—Stomatitis—Methotrexate—ankylosing spondylitis	0.000959	0.00269	CcSEcCtD
Triazolam—Confusional state—Methylprednisolone—ankylosing spondylitis	0.000956	0.00268	CcSEcCtD
Triazolam—Malaise—Dexamethasone—ankylosing spondylitis	0.000953	0.00267	CcSEcCtD
Triazolam—Malaise—Betamethasone—ankylosing spondylitis	0.000953	0.00267	CcSEcCtD
Triazolam—Oedema—Triamcinolone—ankylosing spondylitis	0.00095	0.00267	CcSEcCtD
Triazolam—Syncope—Dexamethasone—ankylosing spondylitis	0.000947	0.00266	CcSEcCtD
Triazolam—Syncope—Betamethasone—ankylosing spondylitis	0.000947	0.00266	CcSEcCtD
Triazolam—Shock—Triamcinolone—ankylosing spondylitis	0.000935	0.00262	CcSEcCtD
Triazolam—Insomnia—Prednisolone—ankylosing spondylitis	0.000935	0.00262	CcSEcCtD
Triazolam—GABRG3—Orphan transporters—ANO6—ankylosing spondylitis	0.000933	0.0425	CbGpPWpGaD
Triazolam—Shock—Methylprednisolone—ankylosing spondylitis	0.000933	0.00262	CcSEcCtD
Triazolam—Loss of consciousness—Dexamethasone—ankylosing spondylitis	0.000928	0.00261	CcSEcCtD
Triazolam—Loss of consciousness—Betamethasone—ankylosing spondylitis	0.000928	0.00261	CcSEcCtD
Triazolam—Paraesthesia—Prednisolone—ankylosing spondylitis	0.000928	0.0026	CcSEcCtD
Triazolam—Tachycardia—Triamcinolone—ankylosing spondylitis	0.000927	0.0026	CcSEcCtD
Triazolam—Tachycardia—Methylprednisolone—ankylosing spondylitis	0.000925	0.0026	CcSEcCtD
Triazolam—Erythema—Prednisone—ankylosing spondylitis	0.00092	0.00258	CcSEcCtD
Triazolam—GABRB1—Orphan transporters—ANO6—ankylosing spondylitis	0.000919	0.0419	CbGpPWpGaD
Triazolam—Hyperhidrosis—Triamcinolone—ankylosing spondylitis	0.000919	0.00258	CcSEcCtD
Triazolam—Hyperhidrosis—Methylprednisolone—ankylosing spondylitis	0.000917	0.00257	CcSEcCtD
Triazolam—Hypertension—Dexamethasone—ankylosing spondylitis	0.000912	0.00256	CcSEcCtD
Triazolam—Hypertension—Betamethasone—ankylosing spondylitis	0.000912	0.00256	CcSEcCtD
Triazolam—Anxiety—Dexamethasone—ankylosing spondylitis	0.000896	0.00252	CcSEcCtD
Triazolam—Anxiety—Betamethasone—ankylosing spondylitis	0.000896	0.00252	CcSEcCtD
Triazolam—Discomfort—Dexamethasone—ankylosing spondylitis	0.000889	0.00249	CcSEcCtD
Triazolam—Discomfort—Betamethasone—ankylosing spondylitis	0.000889	0.00249	CcSEcCtD
Triazolam—Pain—Prednisolone—ankylosing spondylitis	0.000884	0.00248	CcSEcCtD
Triazolam—GABRA6—Orphan transporters—ANO6—ankylosing spondylitis	0.00087	0.0396	CbGpPWpGaD
Triazolam—Oedema—Dexamethasone—ankylosing spondylitis	0.000862	0.00242	CcSEcCtD
Triazolam—Oedema—Betamethasone—ankylosing spondylitis	0.000862	0.00242	CcSEcCtD
Triazolam—Insomnia—Triamcinolone—ankylosing spondylitis	0.000859	0.00241	CcSEcCtD
Triazolam—GABRA4—Orphan transporters—ANO6—ankylosing spondylitis	0.000859	0.0391	CbGpPWpGaD
Triazolam—Insomnia—Methylprednisolone—ankylosing spondylitis	0.000858	0.00241	CcSEcCtD
Triazolam—Ill-defined disorder—Prednisone—ankylosing spondylitis	0.000854	0.0024	CcSEcCtD
Triazolam—Paraesthesia—Triamcinolone—ankylosing spondylitis	0.000853	0.00239	CcSEcCtD
Triazolam—Feeling abnormal—Prednisolone—ankylosing spondylitis	0.000851	0.00239	CcSEcCtD
Triazolam—Paraesthesia—Methylprednisolone—ankylosing spondylitis	0.000851	0.00239	CcSEcCtD
Triazolam—Visual impairment—Methotrexate—ankylosing spondylitis	0.000851	0.00239	CcSEcCtD
Triazolam—Shock—Dexamethasone—ankylosing spondylitis	0.000848	0.00238	CcSEcCtD
Triazolam—Shock—Betamethasone—ankylosing spondylitis	0.000848	0.00238	CcSEcCtD
Triazolam—Dyspnoea—Triamcinolone—ankylosing spondylitis	0.000847	0.00238	CcSEcCtD
Triazolam—Agitation—Prednisone—ankylosing spondylitis	0.000845	0.00237	CcSEcCtD
Triazolam—Tachycardia—Betamethasone—ankylosing spondylitis	0.000841	0.00236	CcSEcCtD
Triazolam—Tachycardia—Dexamethasone—ankylosing spondylitis	0.000841	0.00236	CcSEcCtD
Triazolam—Hyperhidrosis—Betamethasone—ankylosing spondylitis	0.000833	0.00234	CcSEcCtD
Triazolam—Hyperhidrosis—Dexamethasone—ankylosing spondylitis	0.000833	0.00234	CcSEcCtD
Triazolam—GABRR1—Ion channel transport—ANO6—ankylosing spondylitis	0.000833	0.038	CbGpPWpGaD
Triazolam—Malaise—Prednisone—ankylosing spondylitis	0.00083	0.00233	CcSEcCtD
Triazolam—Syncope—Prednisone—ankylosing spondylitis	0.000825	0.00232	CcSEcCtD
Triazolam—Tinnitus—Methotrexate—ankylosing spondylitis	0.000823	0.00231	CcSEcCtD
Triazolam—Anorexia—Betamethasone—ankylosing spondylitis	0.000822	0.00231	CcSEcCtD
Triazolam—Anorexia—Dexamethasone—ankylosing spondylitis	0.000822	0.00231	CcSEcCtD
Triazolam—Fatigue—Triamcinolone—ankylosing spondylitis	0.000819	0.0023	CcSEcCtD
Triazolam—Fatigue—Methylprednisolone—ankylosing spondylitis	0.000817	0.00229	CcSEcCtD
Triazolam—Pain—Triamcinolone—ankylosing spondylitis	0.000813	0.00228	CcSEcCtD
Triazolam—Loss of consciousness—Prednisone—ankylosing spondylitis	0.000809	0.00227	CcSEcCtD
Triazolam—GABRQ—Ion channel transport—ANO6—ankylosing spondylitis	0.000795	0.0362	CbGpPWpGaD
Triazolam—GABRR2—Ion channel transport—ANO6—ankylosing spondylitis	0.000795	0.0362	CbGpPWpGaD
Triazolam—Hypertension—Prednisone—ankylosing spondylitis	0.000794	0.00223	CcSEcCtD
Triazolam—GABRB2—Orphan transporters—ANO6—ankylosing spondylitis	0.000786	0.0358	CbGpPWpGaD
Triazolam—Feeling abnormal—Triamcinolone—ankylosing spondylitis	0.000783	0.0022	CcSEcCtD
Triazolam—Feeling abnormal—Methylprednisolone—ankylosing spondylitis	0.000781	0.00219	CcSEcCtD
Triazolam—Anxiety—Prednisone—ankylosing spondylitis	0.000781	0.00219	CcSEcCtD
Triazolam—Insomnia—Dexamethasone—ankylosing spondylitis	0.00078	0.00219	CcSEcCtD
Triazolam—Insomnia—Betamethasone—ankylosing spondylitis	0.00078	0.00219	CcSEcCtD
Triazolam—Gastrointestinal pain—Methylprednisolone—ankylosing spondylitis	0.000775	0.00218	CcSEcCtD
Triazolam—Paraesthesia—Dexamethasone—ankylosing spondylitis	0.000774	0.00217	CcSEcCtD
Triazolam—Paraesthesia—Betamethasone—ankylosing spondylitis	0.000774	0.00217	CcSEcCtD
Triazolam—Discomfort—Prednisone—ankylosing spondylitis	0.000774	0.00217	CcSEcCtD
Triazolam—Erythema—Methotrexate—ankylosing spondylitis	0.000769	0.00216	CcSEcCtD
Triazolam—GABRA5—Orphan transporters—ANO6—ankylosing spondylitis	0.000763	0.0348	CbGpPWpGaD
Triazolam—Hypersensitivity—Prednisolone—ankylosing spondylitis	0.000761	0.00214	CcSEcCtD
Triazolam—Dysgeusia—Methotrexate—ankylosing spondylitis	0.000753	0.00211	CcSEcCtD
Triazolam—Oedema—Prednisone—ankylosing spondylitis	0.000751	0.00211	CcSEcCtD
Triazolam—GABRA3—Orphan transporters—ANO6—ankylosing spondylitis	0.00075	0.0341	CbGpPWpGaD
Triazolam—Abdominal pain—Methylprednisolone—ankylosing spondylitis	0.000749	0.0021	CcSEcCtD
Triazolam—Decreased appetite—Dexamethasone—ankylosing spondylitis	0.000749	0.0021	CcSEcCtD
Triazolam—Decreased appetite—Betamethasone—ankylosing spondylitis	0.000749	0.0021	CcSEcCtD
Triazolam—Fatigue—Betamethasone—ankylosing spondylitis	0.000743	0.00209	CcSEcCtD
Triazolam—Fatigue—Dexamethasone—ankylosing spondylitis	0.000743	0.00209	CcSEcCtD
Triazolam—Shock—Prednisone—ankylosing spondylitis	0.000739	0.00207	CcSEcCtD
Triazolam—Pain—Betamethasone—ankylosing spondylitis	0.000737	0.00207	CcSEcCtD
Triazolam—Pain—Dexamethasone—ankylosing spondylitis	0.000737	0.00207	CcSEcCtD
Triazolam—GABRA2—Orphan transporters—ANO6—ankylosing spondylitis	0.000737	0.0336	CbGpPWpGaD
Triazolam—Tachycardia—Prednisone—ankylosing spondylitis	0.000733	0.00206	CcSEcCtD
Triazolam—GABRB3—Orphan transporters—ANO6—ankylosing spondylitis	0.000732	0.0333	CbGpPWpGaD
Triazolam—Hyperhidrosis—Prednisone—ankylosing spondylitis	0.000726	0.00204	CcSEcCtD
Triazolam—GABRG2—Orphan transporters—ANO6—ankylosing spondylitis	0.000719	0.0327	CbGpPWpGaD
Triazolam—Anorexia—Prednisone—ankylosing spondylitis	0.000716	0.00201	CcSEcCtD
Triazolam—Ill-defined disorder—Methotrexate—ankylosing spondylitis	0.000713	0.002	CcSEcCtD
Triazolam—Feeling abnormal—Betamethasone—ankylosing spondylitis	0.00071	0.00199	CcSEcCtD
Triazolam—Feeling abnormal—Dexamethasone—ankylosing spondylitis	0.00071	0.00199	CcSEcCtD
Triazolam—Gastrointestinal pain—Dexamethasone—ankylosing spondylitis	0.000705	0.00198	CcSEcCtD
Triazolam—Gastrointestinal pain—Betamethasone—ankylosing spondylitis	0.000705	0.00198	CcSEcCtD
Triazolam—Hypersensitivity—Triamcinolone—ankylosing spondylitis	0.0007	0.00196	CcSEcCtD
Triazolam—Hypersensitivity—Methylprednisolone—ankylosing spondylitis	0.000699	0.00196	CcSEcCtD
Triazolam—Malaise—Methotrexate—ankylosing spondylitis	0.000693	0.00195	CcSEcCtD
Triazolam—Dizziness—Prednisolone—ankylosing spondylitis	0.000683	0.00192	CcSEcCtD
Triazolam—Asthenia—Triamcinolone—ankylosing spondylitis	0.000682	0.00191	CcSEcCtD
Triazolam—Abdominal pain—Dexamethasone—ankylosing spondylitis	0.000682	0.00191	CcSEcCtD
Triazolam—Abdominal pain—Betamethasone—ankylosing spondylitis	0.000682	0.00191	CcSEcCtD
Triazolam—Asthenia—Methylprednisolone—ankylosing spondylitis	0.00068	0.00191	CcSEcCtD
Triazolam—Insomnia—Prednisone—ankylosing spondylitis	0.000679	0.00191	CcSEcCtD
Triazolam—Paraesthesia—Prednisone—ankylosing spondylitis	0.000674	0.00189	CcSEcCtD
Triazolam—Pruritus—Triamcinolone—ankylosing spondylitis	0.000672	0.00189	CcSEcCtD
Triazolam—Pruritus—Methylprednisolone—ankylosing spondylitis	0.000671	0.00188	CcSEcCtD
Triazolam—GABRG3—Ion channel transport—ANO6—ankylosing spondylitis	0.000655	0.0298	CbGpPWpGaD
Triazolam—Chest pain—Methotrexate—ankylosing spondylitis	0.000655	0.00184	CcSEcCtD
Triazolam—Decreased appetite—Prednisone—ankylosing spondylitis	0.000653	0.00183	CcSEcCtD
Triazolam—Dermatitis—Prednisolone—ankylosing spondylitis	0.000651	0.00183	CcSEcCtD
Triazolam—Diarrhoea—Methylprednisolone—ankylosing spondylitis	0.000649	0.00182	CcSEcCtD
Triazolam—Fatigue—Prednisone—ankylosing spondylitis	0.000647	0.00182	CcSEcCtD
Triazolam—Headache—Prednisolone—ankylosing spondylitis	0.000647	0.00182	CcSEcCtD
Triazolam—Discomfort—Methotrexate—ankylosing spondylitis	0.000647	0.00182	CcSEcCtD
Triazolam—GABRB1—Ion channel transport—ANO6—ankylosing spondylitis	0.000645	0.0294	CbGpPWpGaD
Triazolam—Constipation—Prednisone—ankylosing spondylitis	0.000642	0.0018	CcSEcCtD
Triazolam—Confusional state—Methotrexate—ankylosing spondylitis	0.000633	0.00178	CcSEcCtD
Triazolam—Dizziness—Triamcinolone—ankylosing spondylitis	0.000628	0.00176	CcSEcCtD
Triazolam—GABRA1—Orphan transporters—ANO6—ankylosing spondylitis	0.000628	0.0286	CbGpPWpGaD
Triazolam—Dizziness—Methylprednisolone—ankylosing spondylitis	0.000627	0.00176	CcSEcCtD
Triazolam—Feeling abnormal—Prednisone—ankylosing spondylitis	0.000619	0.00174	CcSEcCtD
Triazolam—Asthenia—Dexamethasone—ankylosing spondylitis	0.000619	0.00174	CcSEcCtD
Triazolam—Asthenia—Betamethasone—ankylosing spondylitis	0.000619	0.00174	CcSEcCtD
Triazolam—Gastrointestinal pain—Prednisone—ankylosing spondylitis	0.000614	0.00172	CcSEcCtD
Triazolam—Nausea—Prednisolone—ankylosing spondylitis	0.000614	0.00172	CcSEcCtD
Triazolam—GABRA6—Ion channel transport—ANO6—ankylosing spondylitis	0.00061	0.0278	CbGpPWpGaD
Triazolam—Pruritus—Dexamethasone—ankylosing spondylitis	0.00061	0.00171	CcSEcCtD
Triazolam—Pruritus—Betamethasone—ankylosing spondylitis	0.00061	0.00171	CcSEcCtD
Triazolam—Hyperhidrosis—Methotrexate—ankylosing spondylitis	0.000607	0.0017	CcSEcCtD
Triazolam—Vomiting—Triamcinolone—ankylosing spondylitis	0.000604	0.0017	CcSEcCtD
Triazolam—Vomiting—Methylprednisolone—ankylosing spondylitis	0.000603	0.00169	CcSEcCtD
Triazolam—GABRA4—Ion channel transport—ANO6—ankylosing spondylitis	0.000603	0.0275	CbGpPWpGaD
Triazolam—Dermatitis—Triamcinolone—ankylosing spondylitis	0.000599	0.00168	CcSEcCtD
Triazolam—Anorexia—Methotrexate—ankylosing spondylitis	0.000598	0.00168	CcSEcCtD
Triazolam—Dermatitis—Methylprednisolone—ankylosing spondylitis	0.000597	0.00168	CcSEcCtD
Triazolam—Headache—Triamcinolone—ankylosing spondylitis	0.000595	0.00167	CcSEcCtD
Triazolam—Headache—Methylprednisolone—ankylosing spondylitis	0.000594	0.00167	CcSEcCtD
Triazolam—Abdominal pain—Prednisone—ankylosing spondylitis	0.000594	0.00167	CcSEcCtD
Triazolam—Diarrhoea—Betamethasone—ankylosing spondylitis	0.00059	0.00166	CcSEcCtD
Triazolam—Diarrhoea—Dexamethasone—ankylosing spondylitis	0.00059	0.00166	CcSEcCtD
Triazolam—Dizziness—Betamethasone—ankylosing spondylitis	0.00057	0.0016	CcSEcCtD
Triazolam—Dizziness—Dexamethasone—ankylosing spondylitis	0.00057	0.0016	CcSEcCtD
Triazolam—Insomnia—Methotrexate—ankylosing spondylitis	0.000568	0.00159	CcSEcCtD
Triazolam—Nausea—Triamcinolone—ankylosing spondylitis	0.000564	0.00158	CcSEcCtD
Triazolam—Paraesthesia—Methotrexate—ankylosing spondylitis	0.000563	0.00158	CcSEcCtD
Triazolam—Nausea—Methylprednisolone—ankylosing spondylitis	0.000563	0.00158	CcSEcCtD
Triazolam—Dyspnoea—Methotrexate—ankylosing spondylitis	0.000559	0.00157	CcSEcCtD
Triazolam—Somnolence—Methotrexate—ankylosing spondylitis	0.000558	0.00157	CcSEcCtD
Triazolam—Hypersensitivity—Prednisone—ankylosing spondylitis	0.000553	0.00155	CcSEcCtD
Triazolam—GABRB2—Ion channel transport—ANO6—ankylosing spondylitis	0.000551	0.0251	CbGpPWpGaD
Triazolam—Vomiting—Dexamethasone—ankylosing spondylitis	0.000548	0.00154	CcSEcCtD
Triazolam—Vomiting—Betamethasone—ankylosing spondylitis	0.000548	0.00154	CcSEcCtD
Triazolam—Decreased appetite—Methotrexate—ankylosing spondylitis	0.000545	0.00153	CcSEcCtD
Triazolam—Dermatitis—Dexamethasone—ankylosing spondylitis	0.000543	0.00152	CcSEcCtD
Triazolam—Dermatitis—Betamethasone—ankylosing spondylitis	0.000543	0.00152	CcSEcCtD
Triazolam—Fatigue—Methotrexate—ankylosing spondylitis	0.000541	0.00152	CcSEcCtD
Triazolam—Headache—Dexamethasone—ankylosing spondylitis	0.00054	0.00152	CcSEcCtD
Triazolam—Headache—Betamethasone—ankylosing spondylitis	0.00054	0.00152	CcSEcCtD
Triazolam—Asthenia—Prednisone—ankylosing spondylitis	0.000539	0.00151	CcSEcCtD
Triazolam—Pain—Methotrexate—ankylosing spondylitis	0.000537	0.00151	CcSEcCtD
Triazolam—GABRA5—Ion channel transport—ANO6—ankylosing spondylitis	0.000535	0.0244	CbGpPWpGaD
Triazolam—Pruritus—Prednisone—ankylosing spondylitis	0.000531	0.00149	CcSEcCtD
Triazolam—GABRA3—Ion channel transport—ANO6—ankylosing spondylitis	0.000526	0.024	CbGpPWpGaD
Triazolam—Feeling abnormal—Methotrexate—ankylosing spondylitis	0.000517	0.00145	CcSEcCtD
Triazolam—GABRA2—Ion channel transport—ANO6—ankylosing spondylitis	0.000517	0.0235	CbGpPWpGaD
Triazolam—Diarrhoea—Prednisone—ankylosing spondylitis	0.000514	0.00144	CcSEcCtD
Triazolam—GABRB3—Ion channel transport—ANO6—ankylosing spondylitis	0.000513	0.0234	CbGpPWpGaD
Triazolam—Gastrointestinal pain—Methotrexate—ankylosing spondylitis	0.000513	0.00144	CcSEcCtD
Triazolam—Nausea—Betamethasone—ankylosing spondylitis	0.000512	0.00144	CcSEcCtD
Triazolam—Nausea—Dexamethasone—ankylosing spondylitis	0.000512	0.00144	CcSEcCtD
Triazolam—GABRG2—Ion channel transport—ANO6—ankylosing spondylitis	0.000504	0.023	CbGpPWpGaD
Triazolam—Dizziness—Prednisone—ankylosing spondylitis	0.000497	0.00139	CcSEcCtD
Triazolam—Abdominal pain—Methotrexate—ankylosing spondylitis	0.000496	0.00139	CcSEcCtD
Triazolam—Vomiting—Prednisone—ankylosing spondylitis	0.000477	0.00134	CcSEcCtD
Triazolam—Dermatitis—Prednisone—ankylosing spondylitis	0.000473	0.00133	CcSEcCtD
Triazolam—Headache—Prednisone—ankylosing spondylitis	0.00047	0.00132	CcSEcCtD
Triazolam—Hypersensitivity—Methotrexate—ankylosing spondylitis	0.000462	0.0013	CcSEcCtD
Triazolam—Asthenia—Methotrexate—ankylosing spondylitis	0.00045	0.00126	CcSEcCtD
Triazolam—Nausea—Prednisone—ankylosing spondylitis	0.000446	0.00125	CcSEcCtD
Triazolam—Pruritus—Methotrexate—ankylosing spondylitis	0.000444	0.00125	CcSEcCtD
Triazolam—GABRA1—Ion channel transport—ANO6—ankylosing spondylitis	0.000441	0.0201	CbGpPWpGaD
Triazolam—Diarrhoea—Methotrexate—ankylosing spondylitis	0.000429	0.00121	CcSEcCtD
Triazolam—Dizziness—Methotrexate—ankylosing spondylitis	0.000415	0.00116	CcSEcCtD
Triazolam—Vomiting—Methotrexate—ankylosing spondylitis	0.000399	0.00112	CcSEcCtD
Triazolam—Dermatitis—Methotrexate—ankylosing spondylitis	0.000395	0.00111	CcSEcCtD
Triazolam—Headache—Methotrexate—ankylosing spondylitis	0.000393	0.0011	CcSEcCtD
Triazolam—Nausea—Methotrexate—ankylosing spondylitis	0.000373	0.00105	CcSEcCtD
Triazolam—GABRR1—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.00029	0.0132	CbGpPWpGaD
Triazolam—GABRQ—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.000277	0.0126	CbGpPWpGaD
Triazolam—GABRR2—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.000277	0.0126	CbGpPWpGaD
Triazolam—GABRG3—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.000228	0.0104	CbGpPWpGaD
Triazolam—GABRB1—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.000224	0.0102	CbGpPWpGaD
Triazolam—GABRA6—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.000212	0.00968	CbGpPWpGaD
Triazolam—GABRA4—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.00021	0.00955	CbGpPWpGaD
Triazolam—GABRB2—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.000192	0.00874	CbGpPWpGaD
Triazolam—GABRA1—SIDS Susceptibility Pathways—RUNX3—ankylosing spondylitis	0.000189	0.00859	CbGpPWpGaD
Triazolam—GABRA5—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.000186	0.00849	CbGpPWpGaD
Triazolam—GABRA3—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.000183	0.00834	CbGpPWpGaD
Triazolam—GABRA2—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.00018	0.00819	CbGpPWpGaD
Triazolam—GABRB3—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.000179	0.00814	CbGpPWpGaD
Triazolam—GABRG2—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.000175	0.00799	CbGpPWpGaD
Triazolam—GABRA1—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.000153	0.00699	CbGpPWpGaD
Triazolam—GABRA1—SIDS Susceptibility Pathways—IL1RN—ankylosing spondylitis	0.00013	0.00593	CbGpPWpGaD
Triazolam—GABRA1—SIDS Susceptibility Pathways—IL1A—ankylosing spondylitis	9.37e-05	0.00427	CbGpPWpGaD
Triazolam—GABRA1—SIDS Susceptibility Pathways—IL10—ankylosing spondylitis	9.31e-05	0.00424	CbGpPWpGaD
Triazolam—GABRA1—SIDS Susceptibility Pathways—TNF—ankylosing spondylitis	3.54e-05	0.00161	CbGpPWpGaD
Triazolam—CYP3A7—Metabolism—B3GNT2—ankylosing spondylitis	2.95e-05	0.00134	CbGpPWpGaD
Triazolam—CYP3A5—Metabolism—B3GNT2—ankylosing spondylitis	2.13e-05	0.000971	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism—B3GNT2—ankylosing spondylitis	1.85e-05	0.000841	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism—B3GNT2—ankylosing spondylitis	1.5e-05	0.000685	CbGpPWpGaD
Triazolam—CYP3A4—Metabolism—B3GNT2—ankylosing spondylitis	9.91e-06	0.000452	CbGpPWpGaD
